Skyhawk Expands Huntington's Disease Trial to U.S., Canada, and U.K.
Event summary
- Skyhawk Therapeutics has expanded its Phase 2/3 FALCON-HD clinical trial for SKY-0515 to the U.S., Canada, and the U.K.
- The trial now includes over 20 sites across more than ten countries with over 175 patients enrolled.
- SKY-0515 has shown a 69% reduction in mHTT and a 26% reduction in PMS1, along with improvements in cUHDRS scores.
- The Phase 1/2 trial enrollment is complete, with SKY-0515 demonstrating safety and tolerability across dose levels.
The big picture
Skyhawk's expansion of the FALCON-HD trial marks a significant step in addressing Huntington's disease, a condition with no approved disease-modifying therapies. The company's proprietary SKYSTAR® platform positions it as a key player in developing RNA-modulating therapies for intractable diseases, potentially reshaping treatment paradigms in neurology.
What we're watching
- Clinical Efficacy
- How the reduction in mHTT and PMS1 biomarkers will translate into long-term clinical benefits for Huntington's disease patients.
- Regulatory Approvals
- Whether Skyhawk can maintain regulatory momentum to support global trial expansion and eventual market approval.
- Pipeline Development
- The pace at which Skyhawk advances additional therapies from its SKYSTAR® platform into clinical development by the end of 2027.
Related topics